A vaccine you can keep on a shelf changes everything
In the laboratories of two of Brazil's most storied scientific institutions, a vaccine born from the earliest days of the pandemic has quietly matured into something the world has not yet seen deployed at scale: a dual-protein immunogen designed to outpace the virus's own evolution. SpiN-TEC, developed by UFMG and Fiocruz, awaits regulatory clearance from Anvisa to begin human trials in early 2023, carrying with it not only a novel biological strategy but the practical promise of reaching the unreachable — stable at room temperature, affordable to produce, and built for a world where the virus is not going away.
- Existing COVID-19 vaccines, all targeting the spike protein alone, have shown diminishing effectiveness as variants like Omicron accumulate mutations that help the virus slip past trained antibodies.
- SpiN-TEC's chimera design — fusing the mutable spike protein with the far more stable nucleocapsid protein — represents a direct scientific answer to that vulnerability, forcing the immune system to defend on two fronts at once.
- Animal trials in mice and primates have cleared ethical review and produced encouraging results, including strong T-cell responses against both the original strain and Omicron, published in Nature Communications in August 2022.
- The path to human trials is close but not complete: Anvisa has been guiding researchers through a year-long regulatory process, with final submissions still pending before approval can be granted.
- If cleared, the vaccine's room-temperature stability and low production cost could transform booster campaign logistics in a country where vast distances and limited infrastructure have long complicated vaccine distribution.
Since March 2020, researchers at Brazil's Federal University of Minas Gerais and the Oswaldo Cruz Foundation have been developing a vaccine designed to do what existing shots could not: hold its ground as the virus mutates. By late summer 2022, that vaccine — SpiN-TEC — was on the threshold of human trials, pending approval from Brazil's health regulator, Anvisa.
The vaccine's defining feature is its structure. Where Brazil's four approved vaccines all target the spike protein — the part of the virus most prone to mutation — SpiN-TEC fuses the spike with the nucleocapsid protein, which has remained relatively stable across variants. This chimera design gives the immune system two targets, reducing the virus's room to escape through mutation alone.
The regulatory journey has been deliberate. Researchers submitted their clinical trial request to Anvisa in July 2021, and for over a year have been in ongoing dialogue with the agency, attending technical meetings and fulfilling documentation requirements. The status remains "under technical requirement" — close, but not yet approved. What has been approved is the ethical framework: both the university's ethics committee and Brazil's national review system have cleared the vaccine for human testing.
Animal studies in mice and primates showed SpiN-TEC prevented severe COVID-19 without significant side effects, and August 2022 data published in Nature Communications confirmed robust T-cell responses against both the original coronavirus and Omicron.
Research coordinator Ricardo Gazzinelli has argued that even a largely vaccinated Brazil still needs this vaccine. Beyond its biological advantages, SpiN-TEC is stable at room temperature and inexpensive to produce — qualities that matter enormously in a country of vast distances and uneven infrastructure. The team's Anvisa submission also includes testing the vaccine as a booster, anticipating years of continued circulation. Whether early 2023 brings the first human volunteers into the trial now rests with the regulator.
In the laboratories of Brazil's Federal University of Minas Gerais and the Oswaldo Cruz Foundation, researchers had been working since March 2020 on a vaccine that might do something the world's existing shots could not: protect against COVID-19 without falling victim to the virus's relentless mutations. By late summer of 2022, that vaccine—called SpiN-TEC—was ready to take its next step. If regulators approved, human trials could begin in early 2023.
The vaccine's design was its distinction. While the four vaccines already in use across Brazil targeted only the spike protein of SARS-CoV-2, SpiN-TEC fused two proteins together: the spike and the nucleocapsid. This chimera structure gave it a theoretical advantage. The spike protein, the one the virus uses to invade human cells, had accumulated mutations with each new variant, allowing the virus to evade the antibodies that existing vaccines trained the body to produce. The nucleocapsid protein, by contrast, had remained relatively stable through the virus's evolution. By attacking both, researchers argued, SpiN-TEC could protect against variants without giving the virus an easy escape route.
The path to human testing had been methodical. In July 2021, the research team submitted their request to Brazil's National Health Surveillance Agency, known as Anvisa, to begin clinical trials. For more than a year, they had been in dialogue with regulators, attending technical meetings, addressing requirements, submitting documents. Anvisa confirmed it was guiding the researchers through the process, waiting for final submissions before granting approval. The regulatory status remained listed as "under technical requirement"—close, but not yet cleared.
What had already been cleared was encouraging. The university's ethics committee and the national ethics review system, which serves as the highest authority for evaluating human research protocols in Brazil, had both approved the vaccine for testing. In animal studies, SpiN-TEC had shown it could prevent severe COVID-19 without causing significant side effects in mice and primates. In August 2022, researchers published data in Nature Communications showing the vaccine induced robust T-cell responses against both the original coronavirus strain and the Omicron variant.
Ricardo Gazzinelli, the coordinator of the research at the university's vaccine center, argued that even with much of Brazil's population already vaccinated, a new vaccine remained necessary. Current vaccines had shown weak effectiveness against Omicron. More fundamentally, SpiN-TEC had practical advantages that went beyond biology. RNA-based vaccines required storage at extremely low temperatures, complicating distribution to remote regions. SpiN-TEC could be kept at room temperature. Its production cost was low. These qualities mattered in a country with vast distances and limited resources.
Gazzinelli also saw the vaccine's future beyond initial protection. Booster shots would likely be needed for years to come, and SpiN-TEC could serve that role. The team's request to Anvisa included testing the vaccine's ability to function as a booster dose, to sustain immunity against COVID-19 as the virus continued to circulate and evolve.
The vaccine represented a different technological approach than anything Brazil had deployed so far. CoronaVac, AstraZeneca, Pfizer, and Janssen all relied on different platforms—inactivated virus, viral vector, messenger RNA, and viral vector respectively—but all focused on the spike protein alone. SpiN-TEC's dual-protein strategy was novel in the Brazilian context and potentially significant globally. If human trials confirmed what animal studies suggested, it could offer protection where existing vaccines had shown limitations, and it could reach populations that other vaccines could not easily reach. The question now was whether Anvisa would issue its approval, and whether the early months of 2023 would bring the first volunteers into the trial.
Citações Notáveis
Current vaccines show weak effectiveness against Omicron, making new solutions that target multiple variants essential, and this vaccine can be stored and transported far more easily than RNA-based alternatives.— Ricardo Gazzinelli, vaccine research coordinator at UFMG
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this vaccine targets two proteins instead of one?
Because the spike protein—the one every other vaccine targets—is the part of the virus that mutates most. Each new variant has found ways around the antibodies trained to recognize it. The nucleocapsid protein changes much more slowly. By hitting both, you're attacking a moving target and a stationary one at once.
So this is a hedge against future variants?
Partly. But it's also about what's already here. Omicron has already shown that the current vaccines lose effectiveness. This one was designed with that problem in mind from the start.
The article mentions room-temperature storage. How much does that actually matter?
In a country like Brazil, it matters enormously. RNA vaccines need to be frozen at minus 70 degrees. That means specialized equipment, specialized transport, specialized storage at every clinic. In remote areas, that's often impossible. A vaccine you can keep on a shelf changes the entire logistics of distribution.
If it works, when would people actually get it?
That's still uncertain. The human trials haven't even started yet. But if they go well, the researchers see it as a booster—something people would get after their initial vaccination series, probably repeatedly over the next few years as immunity wanes.
What's the biggest risk at this point?
That the results in animals don't translate to humans. That happens more often than people realize. But the ethical boards have already signed off, and the data they've published is solid. The real hurdle now is just getting Anvisa to say yes.
And if Anvisa approves?
Then in a few months, the first Brazilians will roll up their sleeves for something their country actually made.